

Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement.

Title: Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement.

Publication year: 2020

Journal: Allergy

Authors: Immunoallergy Unit, Careggi University Hospital, Florence, Italy.

Society: European Academy of Allergy and Clinical Immunology

Origin country: International (Europe)

Target countries: Europe

DOI: 10.1111/all.14407

PMID: 32500526

Source: <https://pubmed.ncbi.nlm.nih.gov/32500526/>

Allergy Allergy 3812 phebblackwell 7804028 ALL Allergy 0105-4538 1398-9995
pmc-is-collection-domain yes pmc-collection-title Wiley - PMC COVID-19 Collection PMC7300800
PMC7300800.1 7300800 7300800 32500526 10.1111/all.14407 ALL14407 1 Eaaci Position Paper
Eaaci Position Papers Considerations on biologicals for patients with allergic disease in times of the
COVID-19 pandemic: An EAACI statement VULTAGGIO et al. Vultaggio Alessandra 1 Agache
Ioana <https://orcid.org/0000-0001-7994-364X> 2 Akdis Cezmi A.
<https://orcid.org/0000-0001-8020-019X> 3 Akdis Mubeccel <https://orcid.org/0000-0003-0554-9943> 3
Bavbek Sevim 4 Bossios Apostolos <https://orcid.org/0000-0002-0494-2690> 5 6 7 Bousquet Jean 8
9 10 11 Boyman Onur <https://orcid.org/0000-0001-8279-5545> 12 13 Chaker Adam M. 14 Chan
Susan 15 Chatzipetrou Alexia 16 Feleszko Wojciech 17 Firinu Davide
<https://orcid.org/0000-0002-5768-391X> 18 Jutel Marek 19 20 Kauppi Paula 21 Klimek Ludger 22
Kolios Antonios 10 11 12 23 Kothari Akash <https://orcid.org/0000-0003-1980-161X> 24 Kowalski
Marek L. 25 Matucci Andrea 1 Palomares Oscar <https://orcid.org/0000-0003-4516-0369> 26 Pfaar
Oliver <https://orcid.org/0000-0003-4374-9639> 27 Rogala Barbara
<https://orcid.org/0000-0002-3077-0271> 28 Untersmayr Eva <https://orcid.org/0000-0002-1963-499X>
29 Eiwegger Thomas <https://orcid.org/0000-0002-2914-7829> 24 30 31
thomas.eiwegger@sickkids.ca 1 Immunoallergy Unit Careggi University Hospital Florence Italy
2 Transylvania University Brasov Romania 3 Swiss Institute of Allergy and Asthma Research
(SIAF) University Zurich Davos Switzerland 4 Department of Chest Disease Division of Immunology
and Allergy School of Medicine Ankara University Ankara Turkey 5 Department of Respiratory
Medicine and Allergy Karolinska University Hospital Stockholm Sweden 6 Department of Medicine
Karolinska Institutet Stockholm Sweden 7 Centre for Allergy Research Karolinska Institutet
Stockholm Sweden 8 Charité Universitätsmedizin Berlin Humboldt-Universität zu Berlin Berlin
Germany 9 Department of Dermatology and Allergy Berlin Institute of Health Comprehensive
Allergy Center Berlin Germany 10 MACVIA-France Montpellier France 11 CHU Montpellier
Montpellier France 12 Department of Immunology University Hospital Zurich Zurich Switzerland 13
Faculty of Medicine University of Zurich Zurich Switzerland 14 Department of Otolaryngology TUM
School of Medicine Klinikumrechts der Isar Center for Allergy and Environment Technical University
of Munich Munich Germany 15 School of Immunology & Microbial Sciences United Kingdom King's
College London School of Life Course Sciences King's Health Partners Guy's and St. Thomas'
NHS Foundation Trust London UK 16 Allergy Unit 2 nd Department of Dermatology and
Venereology Medical School National University of Athens University General Hospital "ATTIKON"
Athens Greece 17 Department of Pediatric Allergy and Pneumology Medical University of Warsaw
Warsaw Poland 18 Department of Medical Sciences and Public Health University of Cagliari
Monserrato Italy 19 Department of Clinical Immunology Wroclaw Medical University Wroclaw
Poland 20 ALL-MED Medical Research Institute Wroclaw Poland 21 Department of Allergy
Inflammation Center Helsinki University Hospital and Helsinki University Helsinki Finland 22 Centre

for Rhinology and Allergy Wiesbaden Germany 23 Department of Medicine Beth Israel Deaconess Medical Center Harvard Medical School Boston MA USA 24 Translational Medicine Program Peter Gilgan Centre for Research and Learning Hospital for Sick Children Toronto ON Canada 25 Department of Immunology and Allergy Medical University of Lodz Lodz Poland 26 Department of Biochemistry and Molecular Biology Chemistry School Complutense University of Madrid Madrid Spain 27 Department of Otorhinolaryngology, Head and Neck Surgery Section of Rhinology and Allergy University Hospital Marburg Philipps-Universität Marburg Marburg Germany 28 Department of Internal Diseases Allergology & Clinical Immunology Medical University of Silesia Katowice Poland 29 Institute of Pathophysiology and Allergy Research Center of Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria 30 Departments of Paediatrics and Immunology Division of Immunology and Allergy Food Allergy and Anaphylaxis Program The Hospital for Sick Children University of Toronto Toronto ON Canada 31 Department of Immunology University of Toronto Toronto ON Canada * Correspondence Thomas Eiwegger, The Department of Paediatrics and Immunology, Division of Immunology and Allergy, Food allergy and Anaphylaxis Program, Research Institute, Hospital for Sick Children, University of Toronto, 555 University Ave, Toronto, ON, Canada. Email: thomas.eiwegger@sickkids.ca 06 11 2020 11 2020 75 11 359779 10.1111/all.v75.11 2764 2774 09 5 2020 17 4 2020 11 5 2020 06 11 2020 18 06 2020 25 03 2026 © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency. Abstract The outbreak of the SARS-CoV-2-induced coronavirus disease 2019 (COVID-19) pandemic re-shaped doctor-patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex patients with severe allergic disease. A significant number of the patients are on treatment with biologicals, and clinicians face the challenge to provide optimal care during the pandemic. Uncertainty of the potential risks for these patients is related to the fact that the exact sequence of immunological events during SARS-CoV-2 is not known. Severe COVID-19 patients may experience a “cytokine storm” and associated organ damage characterized by an exaggerated release of pro-inflammatory type 1 and type 3 cytokines. These inflammatory responses are potentially counteracted by anti-inflammatory cytokines and type 2 responses. This expert-based EAACI statement aims to provide guidance on the application of biologicals targeting type 2 inflammation in patients with allergic disease. Currently, there is very little evidence for an enhanced risk of patients with allergic diseases to develop severe COVID-19. Studies focusing on severe allergic phenotypes are lacking. At present, noninfected patients on biologicals for the treatment of asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, or chronic spontaneous urticaria should continue their biologicals targeting type 2 inflammation via self-application. In case of an active SARS-CoV-2 infection, biological treatment needs to be stopped until clinical recovery and SARS-CoV-2 negativity is established and treatment with biologicals should be re-initiated. Maintenance of add-on therapy and a constant assessment of disease control, apart from acute management, are demanded.

pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access no pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement yes pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes source-schema-version-number 2.0 cover-date November 2020 details-of-publishers-convertor Converter:WILEY_ML3GV2_TO_JATSPMC version:6.1.7 mode:remove_FC converted:12.07.2022 Vultaggio A , Agache I , Akdis CA , et al. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement . Allergy . 2020 ; 75 : 2764 – 2774 . 10.1111/all.14407 32500526 PMC7300800